Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis by Fa-Ping Wang (3358667)

“…Pooled analysis revealed significant improvements in FEV₁ (first second forced expiratory volume) (MD = 0.09, 95% CI: 0.06–0.12, <i>I</i>^<i>2</i> = 10%), FEV₁% (MD = 3.75, 95% CI: 1.66–5.83, <i>I</i>^<i>2</i> = 19%), Asthma Quality of Life Questionnaire (AQLQ) score (MD = 0.22, 95% CI: 0.15–0.30, <i>I</i>^<i>2</i> = 0%), decreased blood, sputum eosinophils and asthmatic exacerbation (RR = 0.66, 95% CI: 0.59–0.73, <i>I</i>^<i>2</i> = 51%); peak expiratory flow (PEF) (MD = 5.45, 95% CI: -2.83–13.72, <i>I</i>^<i>2</i> = 0%), histamine PC₂₀ (MD = -0.62, 95% CI: -1.92–0.68, <i>I</i>^<i>2</i> = 0%) or SABA rescue use (MD = -0.11, 95% CI: -0.3–0.07, <i>I</i>^<i>2</i> = 30%) were unaffected; adverse events were not increased (RR = 0.93, 95% CI: 0.89–0.98, <i>I</i>^<i>2</i> = 46%). …”

Fig 7 - by Maria Alice Miranda Bezerra Medeiros (11752002)

Data Sheet 7_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 6_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 1_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 3_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 8_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 4_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 5_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 2_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Effect of BCA treatment on aortic vasoreactivity. by Mohamed Siliman Misha (19232949)

GIRK channels stabilize RMP of NPY neurons. by Youjin Oh (3308670)

MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme by Alexandra Sufit (3270084)

“…GBM cell lines (A172, SF188, U251) were treated in vitro with increasing doses of UNC2025 (50-400nM). …”

Fig 2 - by Maria Alice Miranda Bezerra Medeiros (11752002)

Fig 3 - by Maria Alice Miranda Bezerra Medeiros (11752002)

<i>In Situ</i> TEM Technique Revealing the Deactivation Mechanism of Bimetallic Pd–Ag Nanoparticles in Hydrogen Sensors by Xueqing Wang (210284)

Change in fish functional diversity and assembly rules in the course of tidal marsh restoration by Alain Lechêne (6103274)

“…Environmental filtering tended to decrease in restored and natural intertidal habitats. …”

Phenotypic characteristics of quiescent amastigotes from LT-HSC. by Laura Dirkx (8950205)

Effects of busulfan treatment on CX43 and N-Cadherin. by Lingjun Zhao (21763122)

“…<p>The gap junction protein CX43 (A) and the ectoplasmic specialization-related protein N-Cadherin (B) were detected by immunofluorescence assay. …”

Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate by Jairo E. Perez-Franco (3166050)

“…<i>braziliensis</i> (95.4%) and 35% of the parasites isolated showed a significant decrease in <i>in vitro</i> Glucanatime susceptibility associated with previous administration of the medicament. …”